

PB 137 of 2021

National Health (COVID-19 Supply of Pharmaceutical Benefits) Amendment (Additional Extension) Special Arrangement 2021

I, Elizabeth Flynn, delegate of the Minister for Health and Aged Care, make the following special arrangement under subsection 100(2) of the *National Health Act 1953*.

Dated 17 December 2021

Elizabeth Flynn

Acting First Assistant Secretary

Technology Assessment and Access Division

Department of Health

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (COVID-19 Supply of Pharmaceutical Benefits) Special Arrangement 2020 2

1 Name

 (1)      This instrument is the *National Health (COVID-19 Supply of Pharmaceutical Benefits) Amendment (Additional Extension) Special Arrangement 2021.*

(2)    This instrument may also be cited as PB 137 of 2021.

2 Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | On the day after this instrument is registered |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 100(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (COVID-19 Supply of Pharmaceutical Benefits) Special Arrangement 2020

1 Section 4

Omit “1 January 2022”, substitute “1 April 2022”.

2 Subsection 6(1) (definition of *phone attendance*)

Omit “*Health Insurance (Section 3C General Medical Services – COVID-19 Telehealth and Telephone Attendances) Determination 2020*”, substitute “*Health Insurance (Section 3C General Medical Services – Telehealth and Telephone Attendances) Determination 2021”*.

3 Subsection 6(1) (definition of *telehealth attendance*)

Omit “*Health Insurance (Section 3C General Medical Services – COVID-19 Telehealth and Telephone Attendances) Determination 2020*”, substitute “*Health Insurance (Section 3C General Medical Services – Telehealth and Telephone Attendances) Determination 2021”*.

4 Subsection 6(2)

Omit “*Health Insurance (Section 3C General Medical Services – COVID-19 Telehealth and Telephone Attendances) Determination 2020*”, substitute “*Health Insurance (Section 3C General Medical Services – Telehealth and Telephone Attendances) Determination 2021”*.

5 Paragraph 9(1)(c)

Omit “*Health Insurance (Section 3C General Medical Services – COVID-19 Telehealth and Telephone Attendances) Determination 2020*”, substitute “*Health Insurance (Section 3C General Medical Services – Telehealth and Telephone Attendances) Determination 2021”*.

6 After Section 17

Insert:

17A Continued application of Special Arrangement as in force before commencement of the *National Health (COVID‑19 Supply of Pharmaceutical Benefits) Amendment (Additional Extension) Special Arrangement 2021*

(1) This Special Arrangement, as in force immediately before the commencement of this section, continues to apply on and after that commencement in relation to the supply of a pharmaceutical benefit made under this Special Arrangement before that commencement.

7 Subsection 18(1)

Omit “1 January 2022”, substitute “1 April 2022”.